Navigation Links
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
Date:11/4/2010

CAMBRIDGE, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of VPRIV® (velaglucerase alfa for injection) compared with imiglucerase in patients with type 1 Gaucher disease at the 2010 Annual American Society of Human Genetics (ASHG) in Washington, D.C. The study met its primary endpoint and adds to the growing body of clinical evidence which supports the use of VPRIV in patients who have transitioned from imiglucerase or who are treatment-naive. 

In the 039 (head-to-head) study, adult and pediatric patients with type 1 Gaucher disease were included in a 9-month, global, randomized, double-blind, non-inferiority study comparing VPRIV with imiglucerase in treatment-naive patients aged >/= 2 years, with anemia and either thrombocytopenia or organomegaly. Patients were randomized in a 1:1 ratio to receive either VPRIV or imiglucerase at a dose of 60U/kg via continuous infusion over one hour every other week for 39 weeks (total of 20 infusions per patient). 35 patients in 9 countries were randomized and 34 received the study drug (intent-to-treat [ITT] population was 17 in both the VPRIV and imiglucerase groups). The per-protocol (PP) analysis included 15 patients in each group. Baseline clinical characteristics were generally similar between the 2 groups, although hemoglobin concentrations appeared slightly higher in the VPRIV group.

After 9 months of treatment, hemoglobin concentration improved in both groups. The estimated mean treatment difference for hemoglobin concentration from baseline between patients treated with VPRIV and imiglucerase was 0.14 and 0.16 g/dL in the ITT and PP populations, respectively, with a lower bound of the 97.5% one-sided confidence inte
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... and MILL VALLEY, Calif. ... Sarcoma Alliance today announced a partnership in the ... will sponsor the Sarcoma Alliance Suzanne Renee Leider ... program offers financial assistance to reimburse sarcoma patients ... opinion from a sarcoma specialist. Scientific literature reinforces ...
(Date:9/17/2014)... Sept. 17, 2014  Trovagene, Inc., (NASDAQ:   TROV) ... Alberto Bardelli , Ph.D., has joined the Company,s ... to identify mutations in the kinase genes that are ... is at the Department of Oncology, Torino Medical School, ... . "Alberto,s work in cancer ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3
... , , SANTA FE SPRINGS, Calif., ... in the design and manufacturing of superior air cleaning products, ... year,s exclusive Top 10 Products for Parents listing by Parent ... I look for the safest products available for my children," ...
... , , , ... Obama Administration rejected a plan to allow the wholesale reimportation ... take on the drug industry and secure cheaper prescription for ... percent more for drugs than people in Canada, Australia, the ...
Cached Medicine Technology:IQAir HealthPro Plus Selected as a Top 10 Product for Parents 2IQAir HealthPro Plus Selected as a Top 10 Product for Parents 3Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 2Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 3
(Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
(Date:9/17/2014)... September 17, 2014 According to ... ), the leading global authority in medical device ... and regeneration market is expected to exceed ... into breast reconstruction, hernia repair, dural repair, vaginal ... and dental soft tissue regeneration. , Approximately ...
(Date:9/17/2014)... Kamut International is pleased to announce ... in Michael Angelo’s new “Made With Organic” ready-made, frozen ... lasagna ready made, frozen meal. Michael Angelo’s products feature ... new products align well with Kamut International’s mission to ... wheat must be grown certified organic. , The new ...
(Date:9/17/2014)... PA (PRWEB) September 17, 2014 ... and increase efficiency. Today, Pharmacy Healthcare Solutions, a ... a web-based analysis and forecasting tool that enables ... maximizing the impact of medications on improved patient ... Reporting uses pharmacy purchase data to identify areas ...
(Date:9/17/2014)... HealthDay Reporter , TUESDAY, ... Americans dying from accidental overdoses of narcotic painkillers jumped ... Tuesday. Deaths from overdoses of drugs such as ... per 100,000 people to 5.4 per 100,000, according ... That means about 3,000 people died in 1999 ...
Breaking Medicine News(10 mins):Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 3Health News:Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC 2Health News:Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC 3
... ... for Haiti,s Earthquake Victims, New Campaign Seeks Participants in Healing Service for Chile on ... ... and Master Zhi Gang Sha and the Institute of Soul Healing and Enlightenment, shortly after ...
... ... ... ... ...
... ... ... , ... , , ...
... ... ... ... ...
... of the major cancers in Northeast Thailand. This cancer ... mortality rates. Overexpression of Met, a hepatocyte growth factor ... is correlated with progression of this type of cancer. ... cell scattering, invasion and proliferation. Although a number of ...
... to see the human brain at work, a new generation ... appeal while it is still being designed, according to a ... University. So-called "neuromarketing" takes the tools of modern brain ... somewhat abstract likes and dislikes of customer decision-making. Though ...
Cached Medicine News:Health News:Master Zhi Gang Sha Dedicates Soul Healing Blessings for Humanity Service to Chile's Earthquake Victims 2Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 2Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 3Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 4Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 2Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 3Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 4Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 5Health News:Different signaling pathways of cholangiocarcinoma 2
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
The most traditional style of instrument, a classical punch shape with the parrot beak upper jaw to aid in the capture of tissue....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
Medicine Products: